DEC 26, 2018 7:56 PM PST

Compound Shrinks Tumors of Sarcoma Cells

WRITTEN BY: Nouran Amin

According to a multi-disciplinary study carried out by the University of Illinois, a compound was found to effectively shrink tumors in animal models by targeting receptor proteins on sarcoma cancer cells.

Learn more about sarcoma:

"There's a very poor prognosis with sarcomas. Sarcomas are rare tumors, but they are so heterogeneous that they're very difficult to treat," explained Dipanjan Pan, a professor of bioengineering and in the Carle Illinois College of Medicine and lead author of the study. "The receptor we targeted inside the cancer cells, the orphan nuclear receptor, is a more universal target for the varied sarcomas than markers on the surface of cells. The opportunity is huge, because this receptor is also expressed in other types of solid cancers -- melanoma or liver cancers, for example."

Specifically, the researchers targeted a protein found abundantly in individuals with sarcoma and other cancer cells but present in low concentrations in normal healthy cells—this protein is called the retinoid X receptor (RXR). Most recently, a drug class targeting RXR has been developed. However, the drug was found to be very toxic and comes with limitations. Therefore, researchers were encouraged to look for better compounds that would be most appropriate for targeting RXR in regards to safety and efficacy.

The new compound, shown in green, fits precisely into the active site within the target protein, retinoid X receptor. Image courtesy of Dipanjan Pan via University of Illinois

When the most promising compound was picked out of 20,000 likely candidates, it was synthesized and tested on tissue culture cells. After successful results, the compound was then tested on a sarcoma-pig model. The results, published in Journal of Medicinal Chemistry, shows that tumors successfully shrunk and were less likely to metastasize. No specific toxicity was sobered or measured however, there was some side effects. "We saw that the tumor was shrinking, but that doesn't mean the drug is working the way it's supposed to work," Pan said. "We wanted to make sure that the drug was actively participating in the pathway we intended, and that it wasn't just killing cells because it's toxic.

Source: University of Illinois

 

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 13, 2020
Drug Discovery & Development
Scientists Find Way to Reduce Inflammation from Vaccines
SEP 13, 2020
Scientists Find Way to Reduce Inflammation from Vaccines
Researchers from the University of Chicago have found a new way to reduce vaccine-related inflammation from adjuvants, a ...
SEP 11, 2020
Drug Discovery & Development
Novel Therapeutic for ALS
SEP 11, 2020
Novel Therapeutic for ALS
The TDP-43 protein is a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). A ...
OCT 07, 2020
Technology
Millimeter-Precision Drug Delivery
OCT 07, 2020
Millimeter-Precision Drug Delivery
It is almost impossible to deliver targeted drug therapy via the bloodstream without reaching the entire brain and body ...
NOV 08, 2020
Cannabis Sciences
Can Cannabis Treat Epilepsy?
NOV 08, 2020
Can Cannabis Treat Epilepsy?
There has been growing interest in recent years for cannabis to treat central nervous system disorders. And so far, ther ...
NOV 09, 2020
Drug Discovery & Development
New Immunotherapy Shows Promise for MS
NOV 09, 2020
New Immunotherapy Shows Promise for MS
Researchers from Thomas Jefferson University in Philadelphia are studying an immunotherapy that has shown early pro ...
NOV 22, 2020
Cannabis Sciences
Synthetic Cannabinoids Linked to Increased Deaths in Older Patients with COPD
NOV 22, 2020
Synthetic Cannabinoids Linked to Increased Deaths in Older Patients with COPD
Researchers from St. Michael’s Hospital in Toronto have found that two synthetic cannabinoids available on prescri ...
Loading Comments...